Current methods to reduce the adverse haematological consequences of cardiopulmonary bypass

British Journal of Clinical Practice

Volumn 50, Issue 4, 1996, Pages 203-206

  John, Lch ^a,b   Deverall, P B ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b 4 Clifton Hill Studios ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; HEMOGLOBIN;

BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; HEALTH CARE POLICY; HEART SURGERY; HUMAN; MORBIDITY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTE DYSFUNCTION;

APROTININ; BLOOD COMPONENT TRANSFUSION; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; HEMOSTATICS; HUMANS; POSTOPERATIVE HEMORRHAGE;

EID: 0029973334     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (66)

1. Roche JK, Stengle JM. Open-heart surgery and ihe demand Tor blood. J Am M cd Au<;c 1973:225: 1516-21.
2. Graves EJ. 1991 summary: national hospital discharge survey. virol Health Suit 1993:227: 1-12.
3. Goudnough LT. Johnson MFM, Toy PTCY. and the Transfusion Medicine Academic Award Group. The variability of transfusion practice in coronary bypass surgery. J Ant Med As AW 1991 ; 265: 86-90.
4. Harker LA. Malpass TW, Branson HE el al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with alpha-granule release. Blood 1980: 56: 824-34.
5. Carey JS. Cukingham RA. Carson E. Transfusion therapy in cardiac surgery: impact of the Paul Gann Blood Safety Act in California. American Surgeon 1991: 57: 830-5.
6. Love TR. Hendren WO. O'Keele DD. Daggett WM. Transfusion of predonated autologous blood in elective cardiac surgery. Ann Thonic Surg 1987; 43: 508-12.
7. Schlayer HJ. Peters T, Preisler S et al. Cause and frequency of post transfusion hepatitis after open-heart surgery. Cliniial Investigator 1992: 70: 579-84.
8. Dasarathy S. Misra SC. Acharya SK et al. Prospective controlled study of post-transfusion hepatitis after cardiac surgery in a large referral hospital in India. Livi'f 1992: 12: 115-20.
9. Donahue JG, Munoz A. Ness PM et al. The declining risk of post transfusion hepatitis C virus infection. N £ngl J Med 1992: 327: 369-73.
10. Moat NE. Shore DF, Hvans TW. Organ dysfunction and cardiopulmonary bypas: the role of complement and complement regulatory proteins. Lurop J Ctmliothorai Sur- 1993; 7: 563-73.
11. Louagie Y. Gonzalez E. Jamart J et al. Post cardiopulmonary bypass lung oedema. A preventable complication? CICM 1993; 103: 86-95.
12. Talamanti MS. Lo Cicero J. Hugne WPet al. Early re-exploration of excessive postoperative bleeding lowers wound complication rates in open heart surgery. Aiu Siifg 1987:53: 102-4
13. Zilla P. Fasol R. Groscurth P et al. Blood platelets in cardiopulmonary bypass operations: recovery occurs after initial stimulation rather than continual activation. J Thonic Ctirdiovii'sc Snrg 1989: 97: 379-88.
14. Musial J. Niewiarowski S. Riicinski B et al. Inhibition of platelet adhesion to surfaces of extracoiporeal circuits by disintegrins. Circulation 1990: 82: 261-73.
15. Mamnien HK Koets MH. Washington BC et al. Haeinostasis changes during cardiopulmonary b\pass. Scni Thnnnh lletno Hemostaste 1985; 11: 281-92.
16. Kellon J. Heparin induced thromboeylopenia. fluenioittiMt 1986: 16: 173-S6.
17. Woodman RC'. Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blond 1990: 76: 1680-97.
18. Weniier RK. Lukasiewicz H. Mikuta BS et al. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorai CurdiovaM Sunj 1989: 97: 235-9.
19. Wachtfogel YT, Musial J. Jenkins B et al. Loss of platelet alpha 2 adrenergic receptors during simulated extracoiporeal circulation. Prévention with Pgel. J l.ah CliuMed 1985: 105:601-7.
20. Adelaman B. Michelson AD. Loscalzo J et al. Plasinin effect on platelet glyeoprotein Ib-vWF interaction. Blood 1985: 65: 32-40.
21. George JN. Picketl EB. Saucerman S et al. Platelet surface glycoproteins: studies on resting and activated platelets and platelet membrane microparticles in normal subjects ami observations in patients with ARDS and cardiac surgery. J Clin Invent 1986: 78:340-8.
22. Alkhamis TM. Beissinger RL, Chediak JR. Artificial surface effect on red blood cells and platelets in laminar shear flow. Blood 1990; 75: 1568-75.
23. Peterson DM. Stathopoulos NA. Georgio TD et al. Shear induced platelet aggregation requires vWF and platelet membrane glyeoproteins Ib ami flow Blood 1987: 69: 625-8.
24. Malpass TW. Hanson SR. Savage B et al. Prevention of acquired transient defect in platelet plug formation by infused prostacyclin. Blood 1981: 57: 736-40.
25. Beurling-Harbury C. Galvan CA. Acquired decrease in platelet secretory ADP associated with increased postoperative bleeding in postcardiopulmonarv bypass patients and in patients with severe valvular heart disease. Blood 1978; 52: 13-23.
26. Edmunds LH. Eilison N. Coleman RW et al. Platelet function during cardiacoperation: comparison of membrane and bubble oxygenators. J. Thow Cardiovasc Surgery 1982:83: 805-12.
27. Valeri CR. Cassidy G. Khuri S et al. Hypothermia induced reversible platelet dysfunction. Ann Surg 1987:205: 175-81.
28. Taggart DP. Siddiqni A. Wheatley DJ. Low dose preoperative aspirin therapy. postoperative blood loss and transfusion requirement. Ann Thorac Sni'g 1990; 50; 425-8.
29. John LCH. Rees GM. Kovacs IB. Inhibition of platelet function by heparin. An aetiological factor in postbypass haemorrhage. J Thonic Cardiovasc Siifg 1993; 105:816-22.
30. Holloway DS. Summaria L. Saresara J et al. Decreased platelet numbers and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988; 59: 62-7.
31. Tanaka J, Takao M, Yada I et al. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothor VascAnesth 1989; 3: 181-8.
32. Rhodes GR, Silver D. Periepicardial fibrinolytic activity: relation to cardiac bleeding. Surgery 1975; 78: 230-7.
33. Pickering NJ, Brody JI, Fink GB et al. The behaviour of antithrombin III, alpha 2-macroglobulin and alpha antitrypsin during cardiopulmonary bypass. Am J Clin Palhol 1983; 80: 459-64.
34. Kongsgaard UE, Smith-Erichsen N, Geiran O et al. Different activation patterns in the plasma kallikrein-kinin and complement systems during coronary bypass surgery. Ada Anaesthesiol Scand 1989; 33: 343-7.
35. Weinstein M, Ware JA, Troll J, Salzman E. Changes in vWF during cardiac surgery: effect of desmopressin acetate. Blood 1988; 71: 1648-55.
36. Gollub S. Heparin rebound in open heart surgery. Surg Gvnecol Obstet 1967; 124: 337-46.
37. Ellison N, Beatty CP, Blake DR et al. Heparin rebound: studies in patients and volunteers. J Thorac Cardiovasc Surg 1974; 67: 723-29.
38. Gundry SR, Drongowski RA, Klein MD, Caran AG. Postoperative bleeding in cardiovascular surgery. Does heparin rebound really exist. Am Surg 1989; 55:162-5.
39. Dietrich W, Barakay A, Dilthey G et al. Reduction of homologous blood requirements in cardiac surgery by intra operative aprotinin application clinical experience in 152 cardiac surgical patients. Thorac Cardiovasc Surg 1989; 37:92-8.
40. Bidstrup BP, Royston D, Taylor KM, Sapsford RN. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97: 364-72.
41. Dietrich W, Barankay A, Hahnel CH et al. High-dose aprotinin: three year's experience in 1784 patients. J Cardiothorac Vase Anesth 1992; 6: 324-7.
42. Bidstrup BP, Harrison J, Royston D et al. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centres in the United Kingdom. AH« Thorac Surg 1993; 55:971-6.
43. Havel M. Teufelsbauer H, Knobl P et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass Operation. J Thorac Cardiovasc Surg 1991; 101: 968-72.
44. van Oeveren W, Harder MP, Roozendaal KJ et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788-97.
45. John LCH, Rees GM, Kovacs IB. Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann Thorac Surg 1993:55: 1175-9.
46. del Rossi AJ, Cernainu AC, Botros S et al. Prophylactic treatment of post transfusion bleeding using EACA. Chest 1989; 96: 27-30.
47. Copeland JG, Harker LA, Joist JM, De Vries WC. Bleeding and anticoagulation. Ann Thorac Surg 1989; 47: 88-95.
48. Salzman EW, Weinstein , Weintraub RM et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. N Engl J Med 1986; 314: 1402-6.
49. Rocha E, Llorens R, Paramo JA et al. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass. Circulation 1988; 77: 1319-23.
50. Hackman T, Gascoyne RD, Naiman SC et al. A trial of desmopressin to reduce blood loss in uncomplicated cardiac surgery. N Engl JMed 1989; 321: 1437-43.
51. Longmore DB, Hoyle PM, Gregory A et al. Prostacyclin administration during cardiopulmonary bypass in man. Lancet 1981; 1: 800-3.
52. Malpass TW, Amory DW, Harker LA et al. The effect of prostacyclin infusion on platelet haemostatic function in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1984; 87: 550-5.
53. Cardoso PF, Yamazaki F, Keshavjee S et al. The reevaluation of heparin requirements for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 153-60.
54. Borowiec J, Thelin S, Bagge L et al. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg 1992; 26: 177-85.
55. Ljungberg B, Johnsson H. In vivo effects of low molecular weight heparin fragment on platelet aggregation and platelet dependent haemostasis in dogs. Thromb Haemost 1988; 60: 232-5.
56. John LCH, Rees GM, Kovacs IB. Different anticoagulants and platelet reactivity in cardiac surgical patients. Ann Thorac Surg 1993; 56: 899-902.
57. Blister SJ, Ofosu FA, Heigenhauser GJ et al. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice. Thromb Haemostas 1994; 71: 468-73.
58. del Rossi AJ, Cernainu AC, Vertnees RAet al. Platelet rich plasma reduces post operative blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 100:281-6.
59. Simon TL, Akl BF, Murphy WP. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 1984; 37: 359-364.
60. Britton LW, Eastland T, Dzuiban SW et al. Predonated autologous blood used in elective cardiac surgery. Ann Thorac Surg 1989; 47: 529-32.
61. Petty AF, Jorst J, Sievers H. Reduction of homologous blood requirements by bloodpooling at the onset of cardiopulmonary Bypass. J Thorac Cardiovasc Surg 1994; 107: 1210-4.
62. Manno CS, Hedberg K.W, Kim HC et al. Comparison of the haemostatic effect of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood 1991; 77: 930-6.
63. Babineau TJ, Dzik WH, Bradley CB et al. Réévaluation of current transfusion practices in patients in surgical intensive care units. Am J Surg 1971; 173: 6-18.
64. Hall RI, Schweiger IM, Finlayson DC. The benefit of the Hemonetics cell saver apparatus during cardiac surgery. Canadian J Anaesthesia 1990; 37: 618-23.
65. Boldt J, Zickman B, Fedderson B et al. Six different hemofiltration devices for blood conservation in cardiac surgery. Ann Thorac Surg 1991; 51: 747-53.
66. Dietrich W, Barankay A, Dilthey G et al. Reduction of blood utilization during myocardial revascularization. J Thorac Cardiovasc Surg 1989; 97: 213-9.